Palatin Technologies, Inc. (NYSE Amex:PTN) is a biopharmaceutical company dedicated to the development of peptide, peptide mimetic and small molecule agonist compounds with a focus on melanocortin and natriuretic peptide receptor systems.

Palatin has a diverse pipeline of active development programs targeting melanocortin and natriuretic receptors, including products for treatment of sexual dysfunction, congestive heart failure, obesity and metabolic syndrome.